GlaxoSmithKline (GSK)

See the following -

Is The Pharmaceutical Industry Doing Enough To Increase Access To Essential Medicines?

Charles Moore | Bio News Texas | April 8, 2014

A report in The Lancet Global Health journal, citing the World Health Organization’s World Medicines Situation, notes that despite progress in many countries, about a third of the world’s population still has no regular access to essential medicines, and says responsibility to resolve this problem lies with many, including the pharmaceutical industry.

Read More »

J&J Sets Drug Data Free In ‘YODA’ Collaboration With Yale

Drew Armstrong | Bloomberg | January 31, 2014

Johnson & Johnson (JNJ) will give academics access to data on clinical trials, a move that may prompt more companies to do the same. Read More »

NY Attorney General Confirms Real-Life Conspiracy Among Drug Companies

J.D. Heyes | Natural News | February 21, 2014

The office of the New York Attorney General and the American units of Ranbaxy Laboratories Ltd. and Teva Pharmaceutical Industries Ltd. have come to terms on a settlement involving claims that an agreement between the two Big Pharma companies restricted competition unlawfully. Read More »

Pfizer Shares Software For Biotech Drug Research With Pharma Rivals

Ryan McBride | FierceBiotechIT | June 24, 2013

Pfizer ($PFE) has led the way in an effort to share software and standards for managing data on complex molecules, providing the tech know-how on a precompetitive basis to competitors such as GlaxoSmithKline ($GSK), Roche ($RHHBY) and Bristol-Myers Squibb ($BMY). Read More »

Pharma and Tech Giants Team Up to Design Devices That Can Hack Your Body’s Electrical Signals

Akshat Rathi | Nextgov | August 1, 2016

Electrical signals from the brain govern much of what goes on in the human body. Pharma and tech giants are spending big money to figure out how to hack these signals, a burgeoning field known as “bioelectronics.” GlaxoSmithKline and Verily Life Sciences, an Alphabet subsidiary, are investing more than $700 million over seven years to create a new company, Galvani Bioelectronics. The firm, 55 percent owned by GSK, will have one lab in Stevenage, U.K., and another in San Francisco...

Read More »

Pharmaceutical Companies Told To Slash Price Of Pneumococcal Disease Vaccine

Sarah Boseley | The Guardian | January 20, 2015

Two giant pharmaceutical companies should lower the price of a new vaccine against pneumococcal disease that is needed by children in developing countries, but is unaffordable for some of their governments, say the volunteer doctors of Médecins sans Frontières (MSF)...

Read More »

Pharmaceutical Giant 'Plotted to Destroy Cancer Drugs to Drive Price Up 4,000%

Katie Forster | Independent | April 15, 2017

Leaked internal emails appear to show employees at one of the world’s leading pharmaceutical companies calling for “celebration” over price hikes of cancer drugs, an investigation has revealed. Staff at Aspen Pharmacare reportedly plotted to destroy stocks of life-saving medicines during a price dispute with the Spanish health service in 2014. After purchasing five different cancer drugs from British firm GlaxoSmithKline (GSK), the company tried to sell the medicines in Europe for up to 40 times their previous price, reported The Times...

Read More »

Silicon Valley Was Going to Disrupt Capitalism. Now It’s Just Enhancing It

Evgeny Morozov | The Guardian | August 6, 2016

The tech giants thought they would beat old businesses but the health and finance industries are using data troves to become more, not less, resilient. The chances that, in a few years’ time, people will be able to receive basic healthcare without interacting with a technology company became considerably smaller after recent announcements of two intriguing but not entirely unpredictable partnerships. One is between Alphabet, Google’s parent company, and pharmaceuticals giant GlaxoSmithKline...

Read More »

Sssh! DataWell’s Clear-Cut Priority Is the Protection of Confidentiality

Michael Cape | Super North | March 17, 2016

Everywhere people are, be it out shopping in a supermarket or sitting at home online, they are adding information to their digital footprint – which feeds into what is known as Big Data and so enables them to be traced. The use of Big Data can be beneficial to society, particularly in terms of health – which is why Gary Leeming’s job as director of informatics for the Greater Manchester Academic Health Science Network (AHSN) is to source and use the digital health footprints of patients both their for own benefit and that of clinicians...

Read More »

The Worst Of Ebola May Be Waning But Flu, Drug-Resistant Superbugs Still Lurk

Staff Writer | Malay Mail Online | January 23, 2015

The worst-ever Ebola epidemic is waning, but after ravaging three West African nations and spreading fear from Dallas to Madrid, it has hammered home the message that the world needs a better detective system for emerging diseases...

Read More »

TransCelerate BioPharma Inc. Releases Recommended Approach For Protecting Personal Data In Clinical Study Reports

Press Release | TransCelerate BioPharma Inc. | September 2, 2014

TransCelerate BioPharma Inc. ("TransCelerate") today announced that it has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) that are shared with researchers, patients and others. The document describes an approach to apply when redacting or removing personal information from CSRs and other related clinical trial documents...

Read More »

WATCH: What Doctors Don't Know About The Drugs They Prescribe

Ben Goldacre | Huffington Post | April 5, 2013

TEDTalks can sometimes portray science in triumphalist tones, with fabulous innovations that are changing the world forever. But the real action in science is often around dirty, messy, angry problems, and my TEDTalk is about the dirtiest I've seen yet. Read More »

You Won't Believe the Outrageous Ways Big Pharma Has Bribed Doctors to Shill Drugs

Martha Rosenberg | The Influence | July 18, 2016

At the 2010 meeting of the American Psychiatric Association in New Orleans, a psychiatrist from the East coast shared her anger with me about the recent clamp down on Pharma financial perks to doctors. Before news organizations and the 2010 Physician Financial Transparency Reports (also called the Sunshine Act, part of the Affordable Care Act) reported the outrageous amount of money Pharma was giving doctors to prescribe its new, brand-name drugs, there was almost no limit to what was spent to encourage prescribing...

Read More »

DIA 2014 50th Annual Meeting To Highlight TransCelerate BioPharma Collaboration

Event Details
Type: 
Conference
Date: 
June 15, 2014 (All day) - June 19, 2014 (All day)
Location: 
San Diego Convention Center
111 W Harbor Drive
San Diego, CA 92101
United States

Industry leaders in R&D will examine accomplishments, progress and 2014 line extensions. Susan Cantrell, senior vice president and managing director for DIA Americas, will chair the panel discussion “Collaboration in R&D: What’s New for TransCelerate BioPharma?” during DIA’s 2014 50th Annual Meeting at the San Diego Convention Center from June 15 to 19...

Read More »